Human beings are unique in the animal kingdom when it comes to nutrition.
Rising readmission rates of subsequent sepsis have given urologic surgeon Jeremy Grummet, MBBS, MS, FRACS, pause.
Researchers have proposed that TP prostate biopsies be offered an option to all men.
Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.
Researchers observe benefit in prostate cancer patients with 2 or more adverse pathologic features.
Pelvic lymph node dissection in high-risk patients is 2.5 times more likely in those undergoing open rather than robotic-assisted surgery.
Men with non-palpable tumors had a 46% lower risk of positive surgical margins.
Patients are more than 9 times more likely to die from causes other than PCa, a new study shows.
It is associated with a 34.7% decrease in biochemical recurrence after radical prostatectomy versus patients with blood type A.
The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.
Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.
Drug no better than placebo in preventing erectile dysfunction after radiotherapy for prostate cancer.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
Men who need a prostate biopsy should be offered TP as a possible alternative to TRUS-guided biopsy.
It is associated with a decreased risk of disease progression compared with a wait-and-see approach.
Magnetic resonance imaging can identify men more likely to harbor intermediate- and high-risk tumors.
Higher circulating tumor cell counts are associated with an increased risk of death.
The treatment, however, is associated with a decreased risk of all-cause mortality in men at high risk of disease progression.